Evidence map›Paper›PMID 35037162›Full record

ReviewCurrent heart failure reports2022

Impact of Loop Diuretic on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction.

Cicoira Maria Antonietta, Emiliano Calvi, Andrea Faggiano, Caterina Maffeis, Marco Bosisio, Marco De Stefano, Stefano Carugo, Pompilio Faggiano

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Cicoira Maria AntoniettaCardiology division, University of Verona, Verona, Italy.
Emiliano CalviCardiology Division, University of Brescia, Brescia, Italy.
Andrea FaggianoFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Cardiology Unit, University of Milan, Milan, Italy.
Caterina MaffeisCardiology division, University of Verona, Verona, Italy.
Marco BosisioCardiology Division, University of Brescia, Brescia, Italy.
Marco De StefanoCardiology division, University of Verona, Verona, Italy.
Stefano CarugoFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Cardiology Unit, University of Milan, Milan, Italy.
Pompilio FaggianoCardiovascular Department, Fondazione Poliambulanza, Brescia, Italy. cardiologia@pompiliofaggiano.it.
University of Verona · ITUniversity of Brescia · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITFondazione Poliambulanza Istituto Ospedaliero · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewLoop diuretics are the cornerstone of the treatment of congestion in heart failure patients. The manuscript aims to summarize the most updated information regarding the use of loop diuretics in heart failure. RECENT

findingsDiuretic response can be highly variable between patients and needs to be carefully evaluated during and after the hospitalization. Diuretic resistance can lead to residual congestion which affects prognosis and can be difficult to detect. The effect of loop diuretics on long-term prognosis remains uncertain but patients with advanced heart failure typically have renal dysfunction and are more inclined to develop loop diuretic resistance, which may lead to an incomplete decongestion and thus to a worse prognosis. Loop diuretics are the most potent diuretics available and their use is recommended in order to alleviate symptoms, improve exercise capacity, and reduce hospitalizations in patients with heart failure. Their use should be limited to the lowest dose necessary to maintain euvolemia because a low dose does not increase the risk of decompensation but reduce the risk of adverse effects and allow the up-titration of disease-modifying drugs.

Indexed as

Heart FailureVentricular Dysfunction, LeftDiureticsHumansSodium Potassium Chloride Symporter InhibitorsStroke VolumeDiureticsSodium Potassium Chloride Symporter InhibitorsDecongestionDiuretic resistanceHeart failureLoop diuretics

Identifiers

PMID35037162
OpenAlexW4206474620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.